Canine p-tau217 antibody and antigen (recombinant protein)

 Download 

Product information

Size： 1mg | 10mg | 100mg

Catalog No.	Description	US $ Price (per mg)	First Order Discount	First Order Discount Price
GMP-CAN-p-tau217-Ag01	Recombinant Canine p-tau217 protein	3090
GMP-CAN-p-tau217-Ab01	Anti-Canine p-tau217 mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-CAN-p-tau217-Ab02	Anti-Canine p-tau217 mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-CAN-p-tau217-Ab03	Anti-Canine p-tau217 mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-CAN-p-tau217-Ab04	Anti-Canine p-tau217 mouse monoclonal antibody (mAb)	1953	20%	1562.4

Shipping Costs: $360–$760
Antibodies: $360 Antigens: $760 (Elevated cost due to antigen heterogeneity, post-translational modifications, structural complexity, and specialized handling.)

Product Description

Cat No. of Products	GMP-CAN-p-tau217-Ag01
Product Name	Recombinant Canine p-tau217 protein
Target/Biomarker	Canine Phospho-tau217 (p-tau217)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Canine Phospho-tau217 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in p-tau217 level test of animal Dog/Canine with Alzheimer Disease(AD).
Tag	His
Products description	Recombinant Canine p-tau217 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-CAN-p-tau217-Ab01, GMP-CAN-p-tau217-Ab02, GMP-CAN-p-tau217-Ab03, GMP-CAN-p-tau217-Ab04
Product Name	Anti-Canine p-tau217 mouse monoclonal antibody (mAb)
Target/Biomarker	Canine Phospho-tau217 (p-tau217)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Anti-Canine Phospho-tau217 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in p-tau217 level test of animal Dog/Canine with Alzheimer Disease(AD).
Tag	mFc
Products description	Anti-Canine p-tau217 mouse monoclonal antibody (mAb) was expressed in CHO - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Associated products

Target/Biomarker information

Canine p-tau217, the phosphorylated Tau Protein 217 variant specific to dogs, represents a molecular sentinel that resides within the complex neural landscape of our canine companions. At its core, it is a Tau protein that has undergone a precise biochemical modification – phosphorylation – specifically at residue 217. Tau proteins are typically involved in the stabilization of microtubules within neuronal cells, ensuring proper intracellular transport and the structural integrity of axons. However, in the context of neurodegenerative diseases, the narrative takes a different turn. Phosphorylation events can lead to the misfolding and aggregation of Tau proteins, and canine p-tau217 is no exception. It tends to aggregate and form neurofibrillary tangles (NFTs) within the neural tissues of affected dogs. These NFTs, reminiscent of those observed in human neurodegenerative diseases like Alzheimer's, are a pathological hallmark of various neurodegenerative conditions in dogs. The aggregation of p-tau217 in NFTs contributes to progressive neuronal dysfunction, cognitive decline, and motor disturbances, as seen in conditions such as canine Alzheimer's disease and specific encephalopathies.

About GDU